有毛細胞白血病(HCL)患者におけるベムラフェニブおよびオビヌツズマブとクラドリビンおよびリツキシマブの比較研究
未治療の有毛細胞白血病(HCL)患者を対象とした、ベムラフェニブとオビヌツズマブとクラドリビンとリツキシマブの無作為多施設共同第II相試験
The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Jae Park, MD
- 電話番号:646-608-3743
- メール:parkj6@mskcc.org
研究連絡先のバックアップ
- 名前:Mark Geyer, MD
- 電話番号:646-608-3745
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- まだ募集していません
- Dana Farber Cancer Institute
-
コンタクト:
- Eric Winer, MD
- 電話番号:(617) 632-6876
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- まだ募集していません
- Mayo Clinic Cancer Center
-
コンタクト:
- Sameer Parikh, M.B.B.S.
- 電話番号:507-218-0772
-
-
New Jersey
-
Basking Ridge、New Jersey、アメリカ、07920
- 募集
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
-
コンタクト:
- Jae Park, MD
- 電話番号:646-608-3743
-
Middletown、New Jersey、アメリカ、07748
- 募集
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
コンタクト:
- Jae Park, MD
- 電話番号:646-608-3743
-
Montvale、New Jersey、アメリカ、07645
- 募集
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
コンタクト:
- Jae Park, MD
- 電話番号:646-608-3743
-
-
New York
-
Commack、New York、アメリカ、11725
- 募集
- Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)
-
コンタクト:
- Jae Park, MD
- 電話番号:646-608-3743
-
Harrison、New York、アメリカ、10604
- 募集
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
コンタクト:
- Jae Park, MD
- 電話番号:646-608-3743
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
コンタクト:
- Jae Park, MD
- 電話番号:646-608-3743
-
Uniondale、New York、アメリカ、11553
- 募集
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
コンタクト:
- Jae Park, MD
- 電話番号:646-608-3743
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- 募集
- Ohio State University
-
コンタクト:
- Seema Bhat, MD
- 電話番号:614-293-3196
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients must be ≥ 18 years of age
-
Histologically confirmed classical HCL by the enrolling institution
-
Presence of BRAF V600E mutation as confirmed by PCR, NGS or immunohistochemistry. If patient is known to have negative BRAF mutation, repeat testing is advisable as well as discussion with the main study principal investigator.
-
Has not received any prior therapy for the disease
-
Patients who meet the standard treatment initiation criteria, as defined by ANC ≤1.0, Hgb ≤ 10.0 or PLT ≤100K
-
ECOG performance status of 0 - 2
-
Acceptable pre-study organ function during screening as defined as:
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except in patients with known Gilbert's syndrome who may be enrolled if direct bilirubin ≤ 3 x ULN);
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN; and
- Serum creatinine ≤ 1.5x ULN
-
Electrocardiogram (ECG) without evidence of clinically significant ventricular arrhythmias or ischemia as determined by the investigator and a rate-corrected QT interval (QTc, Bazett's formula) of < 480 msec
-
For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 6 months after discontinuation of vemurafenib and cladribine, and 18 months after discontinuation of rituximab and obinutuzumab
-
For men with female partners of childbearing potential, agreement to use a latex condom and to advise their female partner to use an additional method of contraception during the study and for 6 months after discontinuation of vemurafenib
-
Negative serum pregnancy test within 7 days of commencement of treatment in women of childbearing potential
Exclusion Criteria:
-
Have had previous treatment for HCL, including purine analogs, vemurafenib, rituximab, obinutuzumab, and other investigational agents. Previous treatment with transfusions and other supportive care such as G-CSF and erythropoietin are allowed.
-
Known hypersensitivity to any of the study drugs.
-
Patients with known long QT syndrome or uncorrectable electrolyte abnormalities
-
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
-
Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody
° Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing and take HBV viral prophylaxis such as entecavir.
-
Known infection with HIV or human T-cell leukemia virus 1 (HTLV-1)
-
Active uncontrolled infection, e.g. persistent bacteremia, supplemental oxygen or pressor supports, etc.
-
Live vaccination within 28 days of randomization
-
Patients with concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years
-
Malabsorption syndrome or other condition that precludes enteral route of administration
-
Patients with HCL variant (as defined by absence of expression of CD25)
-
Pregnant or lactating, or intending to become pregnant during the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Vemurafenib plus Obinutuzumab
Patients assigned to the study arm will receive vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered on days 1, 8 and 15 during the cycle 2 and every 4 weeks during the cycle 3 and 4 of treatment. |
Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. |
|
アクティブコンパレータ:Standard treatment of Cladribine plus Rituximab
Patients assigned to the SOC arm will receive cladribine IV on days 1-5 concurrently with rituximab IV per week for 8 times, i.e., weekly x8 from day 1. |
Cladribine IV on days 1-5 concurrently with rituximab. Rituximab on days 1-5 concurrently with rituximab. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
incidences of ≥ grade 3 treatment-related toxicities
時間枠:within 6 months of treatment
|
per CTCAE v5.0 within first 6 months from the start of the treatment to account delayed toxicities of the treatments |
within 6 months of treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
complete remission
時間枠:2 years
|
Response will be determined by the Consensus Resolution response criteria. Complete response (CR)
|
2 years
|
|
partial response
時間枠:2 years
|
Partial response (PR) °A normalization of cytopenias °≥50% reduction in organomegaly and bone marrow hairy cells. |
2 years
|
協力者と研究者
協力者
捜査官
- 主任研究者:Jae Park, MD、Memorial Sloan Kettering Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 免疫系疾患
- 組織型別の新生物
- 血液疾患
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- 白血病
- ヘミックおよびリンパ疾患
- 白血病、有毛細胞
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 核酸、ヌクレオチド、およびヌクレオシド
- アミド
- インドール
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- プリン
- ヌクレオシド
- リボヌクレオシド
- 抗体、モノクローナル、マウス由来
- デオキシリボヌクレオシド
- スルホンアミド
- スルホン
- 2-クロロアデノシン
- アデノシン
- プリンヌクレオシド
- デオキシアデノシン
- リツキシマブ
- ベムラフェニブ
- クラドリビン
- オビヌツズマブ
その他の研究ID番号
- 24-160
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。